Tags

Type your tag names separated by a space and hit enter

Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Clin Neuropharmacol. 1988 Apr; 11(2):168-73.CN

Abstract

Five patients with advanced Parkinson's disease and fluctuations in therapeutic response to levodopa participated in, and four completed, an open label study of the efficacy of Sinemet CR5. Reductions in the number of daily doses and "off" periods as well as the increase in interdose interval and percent "on" time versus standard Sinemet were comparable to those achieved with Sinemet CR4 in these same patients. As compared with Sinemet CR4, there was a greater delay in the occurrence of peak plasma levodopa concentrations, and relative bioavailability was reduced. Sinemet CR5 appears to offer no advantages over Sinemet CR4 in the treatment of response fluctuations in Parkinson's disease.

Authors+Show Affiliations

Department of Neurology, Burke Rehabilitation Center, White Plains, NY 10605.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3378225

Citation

Cedarbaum, J M., et al. "Controlled-release Levodopa/carbidopa. III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease." Clinical Neuropharmacology, vol. 11, no. 2, 1988, pp. 168-73.
Cedarbaum JM, Hoey M, Kutt H, et al. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease. Clin Neuropharmacol. 1988;11(2):168-73.
Cedarbaum, J. M., Hoey, M., Kutt, H., & McDowell, F. H. (1988). Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease. Clinical Neuropharmacology, 11(2), 168-73.
Cedarbaum JM, et al. Controlled-release Levodopa/carbidopa. III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease. Clin Neuropharmacol. 1988;11(2):168-73. PubMed PMID: 3378225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease. AU - Cedarbaum,J M, AU - Hoey,M, AU - Kutt,H, AU - McDowell,F H, PY - 1988/4/1/pubmed PY - 1988/4/1/medline PY - 1988/4/1/entrez SP - 168 EP - 73 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 11 IS - 2 N2 - Five patients with advanced Parkinson's disease and fluctuations in therapeutic response to levodopa participated in, and four completed, an open label study of the efficacy of Sinemet CR5. Reductions in the number of daily doses and "off" periods as well as the increase in interdose interval and percent "on" time versus standard Sinemet were comparable to those achieved with Sinemet CR4 in these same patients. As compared with Sinemet CR4, there was a greater delay in the occurrence of peak plasma levodopa concentrations, and relative bioavailability was reduced. Sinemet CR5 appears to offer no advantages over Sinemet CR4 in the treatment of response fluctuations in Parkinson's disease. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/3378225/Controlled_release_levodopa/carbidopa__III:_Sinemet_CR5_treatment_of_response_fluctuations_in_Parkinson's_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=3378225.ui DB - PRIME DP - Unbound Medicine ER -